TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05431270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT199
Description: PT199 is an anti-CD73 mAb with a differentiated mechanism of action.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT199
Description: PT199 is an anti-CD73 mAb with a differentiated mechanism of action.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT199
Description: PT199 is an anti-CD73 mAb with a differentiated mechanism of action.
Study: NCT05678309

Intervention type: OTHER
Intervention: Questionnaires
Description: At inclusion, at 6 months and every year, the patient will respond to 5 questionnaires : Brest questionnaire, 5-D itch scale, Dermatology Life Quality Index, Itchy Quality of Life and Hospital Anxiety and Depression Scale
Study: NCT04470674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab 1500 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: pemetrexed 500 mg/m2
Study: NCT05431270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PT199
Description: PT199 is an anti-CD73 mAb with a differentiated mechanism of action.
Study: NCT05303792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Given IV
Study: NCT05431270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Anti-PD-1 monoclonal antibody 200 mg Q3W, inhibits the lymphocytes PD-1 receptors, blocking the ligands that would deactivate it and prevent an immune response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine + nab-Paclitaxel
Description: Dosing is per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Dosing is per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dosing is per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dosing is per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin + Pemetrexed
Description: Dosing is per Standard of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Carboplatin + Pemetrexed
Description: Dosing is per Standard of Care.
Study: NCT04871893

Intervention type: DEVICE
Group type: OTHER
Intervention: multiECCO2R blood-gas exchanger
Description: Treatment with the blood-gas exchanger multiECCO2R for CO2 removal
Study: NCT05361187

Intervention type: DEVICE
Intervention: BOBBY™ Balloon Guide Catheter intended for use in neurovascular procedures, performing or as an adjunctive device
Description: The BOBBY™ BGC used during a mechanical thrombectomy procedure (stent retriever alone, contact aspiration alone or stent retriever and contact aspiration) and according to the instruction for use (IFU).
Study: NCT06157216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRD-guided therapy
Description: MRD negative stage II gastric cancer: Observation; MRD negative stage III gastric cancer: S1 (40-60 mg, PO, bid, d1-d14 q3w); MRD positive stage II/III gastric cancer: XELOX (Oxaliplatin 130mg/m2, d1 +Capecitabine 1000mg/m2，PO. bid, d1-14, q3w) or SOX (Oxaliplatin 130mg/m2, d1 +S-1 40-60 mg, PO. bid, d1-14, q3w); MRD-negative patients will receive XELOX or SOX if MRD becomes positive.
Study: NCT05592366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Care Partner Hospital Assessment Tool
Description: Complete the adjusted CHAT as well as demographic and caregiving questionnaires during and after loved one's hospitalization.
Study: NCT05141006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOTOX
Description: Injection into the bladder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BOTOX
Description: Injection into the bladder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for BOTOX
Description: Injection into the bladder
Study: NCT05806788

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binge Eating Syndrome Treatment (BESTOW)
Description: The BESTOW program involves discussions as well as written and behavioral activities. Participants will also be asked to complete activities, or 'homework,' in between sessions that will help to stop binge eating and to improve eating habits.
Study: NCT05313321

Intervention type: DEVICE
Intervention: Primary total hip arthroplasty receiving the Insignia Stem
Description: Patients receiving the Insignia Stem and associated Stryker Acetabular Component for total hip arthroplasty
Study: NCT06074510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Piflufolastat F 18 Intravenous Solution [PYLARIFY]
Description: Participants will receive a single dose of 333 MBq (9 mCi) \[296 MBq-370 MBq (8 mCi - 10 mCi)\] PYLARIFY injection followed by a single whole-body PET/CT or PET/MRI scan acquired at 1 to 2 hours post-dosing
Study: NCT05409989

Intervention type: DEVICE
Group type: OTHER
Intervention: FRED™ X™
Description: The FRED™ X™ System is indicated for use in the internal carotid artery from the petrous segment to the terminus for the endovascular treatment.
Study: NCT06470282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given intravenously (IV)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Undergo standard of care, IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Undergo standard of care, IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Undergo standard of care, IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy (IMRT)
Description: Undergo standard of care, IMRT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transurethral Resection of Bladder Tumor
Description: Undergo TURBT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy (CS)
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy (CS)
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy (CS)
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystoscopy (CS)
Description: Undergo cystoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging
Study: NCT06082115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical and Occupational Therapy Program
Description: The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical and Occupational Therapy Program
Description: The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected Physical and Occupational Therapy Program
Description: The selected physical and occupational therapy program include:- A-Physical therapy program contains neurodevelopmental technique for U.L \& L.L (U.L \& L.L approximation, U.L \& L.L weight bearing exercises), stretching exercises for U.L \& L.L muscles, strengthening exercises for antispastic group of U.L \& L.L muscles, facilitation of postural reactions, facilitation of gait training and, ascending and descending stairs.~B-Occupational therapy program contains transfer cube from one hand to hand, reaching to mouth (eating lollipop), throwing and catching ball and, clapping with both hands.
Study: NCT06203795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation dosing
Description: Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation dosing
Description: Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation dosing
Description: Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anticoagulation dosing
Description: Patients are dialyzed with only one quarter of their regular anticoagulation dose during the sessions on Tuesday and Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.
Study: NCT05115734

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum acylcarnitine profiling
Description: Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA).

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum acylcarnitine profiling
Description: Blood samples are collected through a central or peripheral venous line placed for clinical use, or through venous punction. Blood will be drawn into a serum gel tube (BD Vacutainer, Becton, Dickinson and Company, Franklin Lakes, NJ, USA), before being centrifuged (3500 rpm, 15 min, 4°C). Supernatant will be frozen at -20°C and stored for later analysis.~Serum ACs concentrations (free carnitine (C0), C2-, C3-, C3DC-, C4-, C4-OH-, C4-DC-, C5-, C5:1-, C5-OH-, C5DC-, C6-, C6-OH-, C6-DC-, C8-, C8:1-, C10-, C10:1-, C10:2-, C12-, C12:1-, C14-, C14:1-, C14:2-, C14-OH-, C16-, C16:1-, C16-OH-, C16-1-OH-, C17-, C18- ,C18:1-, C18:2-, C18-OH-, C18:1-OH-, C18:2-OH-carnitine) will be determined on a TQ5500 tandem mass spectrometer (Sciex, Framingham, MA, USA).
Study: NCT04937829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1569912
Description: BI 1569912

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05443932

Intervention type: DRUG
Group type: OTHER
Intervention: Dapagliflozin
Description: 10mg Dapagliflozin daily for 8 weeks

Intervention type: DRUG
Group type: OTHER
Intervention: Hydrochlorothiazide
Description: 50mg Hydrochlorothiazide daily for 8 weeks
Study: NCT05354752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VC005 tablets
Description: VC005 groups repeat administration for 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VC005 Placebo tablets
Description: VC005 placebo groups repeat administration for 7 days
Study: NCT06082115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: The mirror therapy program include tasks of manipulative and grasping skills that performed by the non-affected hand in-front of mirror while the affected hand behind the mirror. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-Oriented Training
Description: The task-oriented training program include tasks of manipulative and grasping skills that performed by the affected hand based on repetition practice. These tasks contain building towers, rolling dough, transferring cup from one place to another place, turning cards, moving keys, drawing circle and, grasps various objects with different size, shape and weight (ball, markers, pegs and brushes).
Study: NCT05270460

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS12852
Description: PCS12852 oral tablet administered once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCS12852
Description: PCS12852 oral tablet administered once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator oral tablet administered once daily
Study: NCT06203795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood is sampled at start and at 10, 30, 60, 180, and 240 min after dialysis start for the 4 hours dialysis session, and at start and 10 and 180 min after dialysis start for the 3 hours dialysis session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of the dialysis session
Description: Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of the dialysis session
Description: Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of the dialysis session
Description: Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Duration of the dialysis session
Description: Patients have a washout with their regular dialysis duration on Saturday, a study session of 4 hours dialysis on Tuesday, and a study session of 3 hours dialysis on Thursday

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choice of the hemodialyzer
Description: Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choice of the hemodialyzer
Description: Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Choice of the hemodialyzer
Description: Patients are dialyzed with one of the four dialyzers during the entire week, starting at Saturday (i.a. Saturday, Tuesday and Thursday). Block randomization is performed per two weeks. In week 1 and 2, patients are dialyzed with the FX CorAL 800 and the FX 800 Cordiax. In week 3 and 4 of the study, patients are dialyzed with the Solacea 19H and the Xevonta Hi20.
Study: NCT06470282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo CT imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging
Study: NCT05276544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Preparation and follow-up of diet program.
Study: NCT04913103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin
Description: treatment by a study drug polatuzumab-vedotin, i.v.
Study: NCT06470282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo MRI imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET Scan, may be combined with CT (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET Scan, may be combined with CT (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET Scan, may be combined with CT (PET/CT)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Undergo PET Scan, may be combined with CT (PET/CT)
Study: NCT06330584

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nasal Spray 0 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0 mg midazolam/spray) in each nostril, i.e., no active compound

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Nasal Spray 0.45 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.45 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 0.9 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Nasal Spray 0.9 mg/spray
Description: A unit-dose nasal spray will be used for the intervention.~1 spray (= 0.1 μl = 0.9 mg midazolam/spray) in each nostril, i.e., total dose of midazolam 1.8 mg
Study: NCT06006507

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: no exercise will be given

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: In line with the recommendation of the World Health Organization, the exercise group will do 150 minutes of moderate-intensity walking a week and strengthening exercises prepared by the physiotherapist two days a week. Strengthening exercises will be taught by the physiotherapist in a session with the people in the exercise group in groups of five, and then exercise lists will be given to the people on digital exercise platform, where there are video narrations of the exercises. In addition, the participants will be asked to do balance exercises and macular exercise.
Study: NCT06326047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0519-0130
Description: NNC0519-0130 will be administered subcutaneously.
Study: NCT04913103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: treatment by a study drug bendamustin i.v.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: treatment by a study drug rituximab, i.v.
Study: NCT05276544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Preparation and follow-up of diet program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Dietary intervention: Preparation and follow-up of diet program.
Study: NCT06108791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FIO2=0.8
Description: the concentration of intraoperative inspired fraction of oxygen is 80% oxygen + 20% air

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FIO2=0.33
Description: the concentration of intraoperative inspired fraction of oxygen is 33% oxygen + 66% air